Qualtech successfully conducted its webinar on October 29, 2026, providing medical device manufacturers and regulatory professionals with an overview of key regulatory developments in Thailand and Malaysia. The session covered Thailand's updated change notification requirements and registration pathways, alongside Malaysia's regulatory reliance programmes, change management guidance, labelling requirements, and designated medical devices.

Presented by Qualtech's Thailand and Malaysia regulatory specialists, the webinar also addressed practical considerations for manufacturers planning to enter or expand their presence in these markets.

1. Thailand: Key Regulatory Updates in 2026

1.1. Updated Change Notification Requirements

Thailand introduced significant updates to its medical device change notification framework in 2026, expanding the categories of changes and clarifying review requirements.

Key developments include:

  • March 2026: Introduction of the second CN Guideline, expanding the framework to 17 major and 18 minor change topics. It also introduced five automatic-approval topics for Class 2–4 devices, while certain Class 1 changes became subject to official review.
  • August 2026: Introduction of updated CN timelines and fees, with processing times depending on the number of change topics included in each application.

Certain changes still require a new registration rather than a change notification, including changes in product ownership, changes in risk classification that affect the type of approval certificate, the addition of products with a different generic name, and the addition of products that cannot be grouped under the existing registration criteria

1.2. Change Notification Timelines and Fees

Change notifications are categorized according to their review requirements:

  • Major and Minor Changes (Class 2–4): Require technical document evaluation by Thai FDA reviewers or external experts.
  • Automatic Approval: Eligible changes are automatically approved through the system. A THB 500 application fee applies to Class 2–4 devices, while Class 1 changes are free.
  • Class 1 Changes Requiring Review: Certain changes require official document evaluation, with an external expert fee of THB 15,000 where applicable.

Review timelines depend on the number and combination of change topics. For changes not approved by a reference country, processing may range from immediate system approval to 85 working days when expert review is required.

The application and expert evaluation fees presented during the webinar were:

Classification Application fee Expert fee Total
Class 2–3 THB 500 THB 24,000 THB 24,500
Class 4 THB 500 THB 30,000 THB 30,500

Manufacturers should carefully assess the applicable change category before submission, as selecting an incorrect notification topic may result in rejection.

1.3. Registration Pathways: Full, Abridged and Reliance

Thailand offers three registration pathways for Class 2–4 medical devices:

  • Full Pathway: For devices without prior approval from recognized reference authorities; requires a full technical dossier.
  • Abridged Pathway: For eligible devices approved by GHTF countries, including Australia, Canada, the EU, Japan, and the USA, with approval held for more than one year.
  • Reliance Pathway: Allows eligible devices to leverage approvals from recognized authorities, including Singapore HSA and Malaysia MDA.

The Abridged and Reliance pathways offer simplified documentation and potentially reduce evaluation time by approximately three months.

The Abridged Pathway can exempt certain supporting documents, including specified pre-clinical test reports, Clinical Evaluation Reports (CERs), and risk analysis. Meanwhile, the Reliance Pathway allows manufacturers to reuse harmonized documentation prepared for Singapore or Malaysia, subject to applicable requirements. The Full pathway also offers flexibility, as it does not require the device to hold prior market approval in any other country to be eligible for registration in Thailand.

1.4. Upcoming Developments: Refurbished Devices and UDI

Two additional developments are worth monitoring:

  • Refurbished Medical Devices: A draft proposal aims to allow registration of specified refurbished imaging devices. Proposed requirements include compliance with IEC 63077:2019, a certified quality management system covering refurbishment activities, and appropriate refurbished-device labelling. An official announcement was expected following completion of the public hearing.
  • Unique Device Identification (UDI): Implementation is under preparation, initially focusing on dermal fillers and thread lifts. Although not yet mandatory at the time of the webinar, manufacturers were encouraged to prepare UDI master data for future submission to the Thai FDA database.

2. Malaysia: Key Regulatory Updates in 2026

2.1. Regulatory Reliance Programmes

Malaysia's MDA continues to develop regulatory reliance arrangements with other authorities to facilitate medical device registration.

The webinar highlighted three key developments:

  • Singapore HSA: Class B, C, and D devices registered in Singapore can continue to use the MDA Verification Route.
  • Thailand FDA: The reliance arrangement is fully implemented for Class B, C, and D devices, allowing eligible Thai FDA-approved devices to bypass full evaluation.
  • China NMPA: Pilot Phase 2 involved collaborative joint evaluation of eligible applications of general medical devices and in vitro diagnostic (IVD) medical device between MDA and NMPA from July 1 to September 30, 2026.

These arrangements provide opportunities for manufacturers to leverage existing approvals when planning market entry into Malaysia, subject to eligibility requirements.

2.2. New Change Management Guidance: MDA/GD/0072

Malaysia introduced its first edition of MDA/GD/0072: Change Management for Registered Medical Devices, which will replace the existing MDA/GD/0020: Change Notification for Registered Medical Device guidance.

The new guidance provides a more structured approach to change management, including clearer categorization, reporting requirements, and assessment pathways.

It is scheduled to take effect with the launch of MeDC@St 3.0 in December 2026. Until then, MDA/GD/0020 remains applicable.

2.3. Labelling and Anti-Counterfeiting Requirements

The webinar highlighted two important developments:

  • Foreign Manufacturer Information: Medical device labels must include the foreign manufacturer's name and address. Additional contact details, such as email, telephone number, or website, are optional for technical assistance. This requirement is effective immediately.
  • Hologram Security Labels: Malaysia is in the process of implementing hologram labels to help identify genuine MDA-registered medical devices and prevent counterfeit or unregistered products. Additional information regarding the implementation framework and effective date is pending.

Manufacturers and registration holders should review their labelling arrangements and monitor the applicable implementation requirements.

2.4. Designated Medical Devices: Medical Device Order 2026

The Medical Device Order 2026 covers devices primarily used in aesthetic, therapeutic, and clinical settings. These products must meet applicable Malaysian regulatory requirements for quality, safety, and performance before being marketed or used in Malaysia.

Examples include medical lasers, High-Intensity Focused Ultrasound (HIFU) devices, and liposuction devices.

Manufacturers and distributors should assess whether their products fall within the scope of this Order.

3. Key Takeaways

The webinar highlighted the importance of understanding evolving regulatory requirements when planning medical device market entry in Thailand and Malaysia.

Thailand

  • Review updated change notification categories and applicable review timelines.
  • Assess eligibility for Full, Abridged, or Reliance registration pathways.
  • Monitor upcoming requirements for refurbished devices and UDI.
  • Ensure compliance with product labelling and advertising requirements.

Malaysia

  • Explore regulatory reliance opportunities through Singapore HSA and Thailand FDA.
  • Prepare for the transition to MDA/GD/0072.
  • Review foreign manufacturer labelling and anti-counterfeiting requirements.
  • Assess the applicability of Medical Device Order 2026.
  • Plan re-registration and monitor upcoming import permit arrangements.

For manufacturers planning expansion across ASEAN, leveraging existing registrations and technical documentation can help streamline regulatory preparation. However, each market has its own requirements and eligibility criteria that should be assessed early.

Qualtech provides end-to-end regulatory and market-entry support across ASEAN and other international markets, assisting manufacturers with product classification, regulatory strategy, technical documentation, product registration, and local regulatory requirements.

Planning your medical device market entry in Thailand, Malaysia, or other ASEAN markets?

Contact us today to discuss your product registration strategy and how our regional regulatory teams can support your expansion plans.

分享: